摘要:
The present invention provides methods for rapid forensic analysis of mitochondrial DNA and methods for characterizing heteroplasmy of mitochondrial DNA, which can be used to assess the progression of mitochondrial diseases.
摘要:
An immunological assay method for detection of all Haemophilus influenzae strains in respiratory tract infection, otitis media or sepsis in infants or children, said method comprising measuring the amount of the P6 antigen contained in a test sample from a patient and employing a polyclonal antibody which recognizes the P6 antigen of Haemophilus influenzae, wherein said method employs an ELISA system or an immunochromatography assay system.
摘要:
Provided is an immunoassay method whereby all Haemophilus influenzae strains can be simultaneously detected at a high sensitivity. Specifically provided is a method for immunoassaying all Haemophilus influenzae strains characterized in that an antibody that recognizes P4 antigen or P6 antigen of influenza viruses is used.
摘要:
The present invention provides methods for rapid forensic analysis of mitochondrial DNA and methods for characterizing heteroplasmy of mitochondrial DNA, which can be used to assess the progression of mitochondrial diseases.
摘要:
The present invention provides methods for rapid forensic analysis of mitochondrial DNA and methods for characterizing heteroplasmy of mitochondrial DNA, which can be used to assess the progression of mitochondrial diseases.
摘要:
A system, method and computer program product for controlling disease at an end user location, including (a) testing a range of candidates including at least one of: (i) Bacillus species, (i) Bacillus strains, (iii) species of beneficial bacteria (iv) strains of beneficial bacteria and (v) strains of beneficial bacterial viruses, against samples including at least one of pathogenic Vibrio, Gram negative pathogenic bacteria and Gram positive pathogenic bacteria taken from an end user location; (b) performing at least one of the following steps: (i) selecting one or more of the candidates that one of inhibit and attack at least one of the samples by direct inhibition of at least one of in situ antibiotic production, competitive exclusion, production of enzymes that degrade quorum sensing molecules, and (ii) testing a range of quorum sensing inhibitor compounds against the samples; and (c) performing the steps (a) and (b) for the end user location, including one of a country, major region and individual end user location, to target microbial technology to use in bio-control of disease specific to the end user location.